Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BCRX 
BioCryst Pharmaceuticals Inc (BCRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: BCRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.73
1 Year Target Price $16.73
| 6 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.12% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.75B USD | Price to earnings Ratio - | 1Y Target Price 16.73 |
Price to earnings Ratio - | 1Y Target Price 16.73 | ||
Volume (30-day avg) 12 | Beta 1.1 | 52 Weeks Range 6.01 - 11.31 | Updated Date 08/13/2025 |
52 Weeks Range 6.01 - 11.31 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate 0.01 | Actual 0.15 |
Profitability
Profit Margin -6.41% | Operating Margin (TTM) 18.23% |
Management Effectiveness
Return on Assets (TTM) 7.46% | Return on Equity (TTM) -1925.37% |
Valuation
Trailing PE - | Forward PE 128.21 | Enterprise Value 2195973590 | Price to Sales(TTM) 3.14 |
Enterprise Value 2195973590 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 3.94 | Enterprise Value to EBITDA 34.62 | Shares Outstanding 209920000 | Shares Floating 207688976 |
Shares Outstanding 209920000 | Shares Floating 207688976 | ||
Percent Insiders 1.26 | Percent Institutions 85.49 |
Upturn AI SWOT
BioCryst Pharmaceuticals Inc
Company Overview
History and Background
BioCryst Pharmaceuticals, Inc. was founded in 1986. Initially focused on structure-guided drug design, it has evolved into a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel small molecule medicines that address unmet medical needs.
Core Business Areas
- Hereditary Angioedema (HAE): BioCryst's primary focus is on developing and commercializing treatments for HAE, with ORLADEYO as its flagship product.
- Complement Inhibition: The company is also developing other compounds targeting complement inhibition for various autoimmune and inflammatory diseases.
Leadership and Structure
BioCryst is led by CEO Jon Stonehouse. The company has a typical biopharmaceutical organizational structure with departments focused on research and development, commercial operations, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- ORLADEYO (berotralstat): ORLADEYO is an oral, once-daily treatment for the prevention of HAE attacks in adult and pediatric patients 12 years and older. Competitors include Takeda's TAKHZYRO and CSL Behring's HAEGARDA. Global net revenue for 2023 was approximately $325.0 million
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and strong competition. The market for HAE treatments is growing due to increased awareness and improved diagnosis rates.
Positioning
BioCryst is a key player in the HAE market with ORLADEYO, offering a convenient oral option compared to injectable treatments. Their competitive advantage lies in the oral administration and a targeted mechanism of action.
Total Addressable Market (TAM)
The total addressable market for HAE treatments is estimated to be in the billions of dollars annually. BioCryst is positioned to capture a significant share of this market with ORLADEYO and potential future products.
Upturn SWOT Analysis
Strengths
- Oral HAE treatment (ORLADEYO)
- Targeted drug design expertise
- Growing revenue and market share
- Strong intellectual property protection
Weaknesses
- Reliance on a single product (ORLADEYO)
- Competition from established players
- High R&D expenses
- Vulnerability to patent challenges
Opportunities
- Expanding ORLADEYO to new markets
- Developing new indications for ORLADEYO
- Advancing pipeline programs targeting complement inhibition
- Potential acquisitions or partnerships
Threats
- Competition from new HAE treatments
- Patent expiration of ORLADEYO
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- TAK (Takeda Pharmaceutical Company Limited), CSL (CSL Behring)
- KALV (KalVista Pharmaceuticals)
Competitive Landscape
BioCryst competes with established pharmaceutical companies in the HAE market. ORLADEYO's oral administration provides a competitive advantage. Their pipeline programs represent future growth opportunities.
Growth Trajectory and Initiatives
Historical Growth: BioCryst has experienced significant revenue growth in recent years due to the commercial success of ORLADEYO.
Future Projections: Analyst estimates suggest continued revenue growth driven by ORLADEYO and potential pipeline advancements. Specific revenue projections are dependent on analyst forecasts.
Recent Initiatives: Recent initiatives include expanding ORLADEYO's availability globally and advancing clinical trials for new indications and pipeline programs.
Summary
BioCryst Pharmaceuticals is strongly positioned in the HAE market with Orladeyo, which drives revenue growth. However, its reliance on a single product makes it vulnerable. Expanding to new markets and advancing pipeline programs are crucial. Competition from established players is a key challenge to watch.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioCryst Pharmaceuticals Investor Relations Website
- SEC Filings
- Analyst Reports (FactSet, Bloomberg)
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share and competitor data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioCryst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 1994-03-03 | CEO & Executive Director Mr. Jon P. Stonehouse | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 580 | Website https://www.biocryst.com |
Full time employees 580 | Website https://www.biocryst.com | ||
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.